Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
At-Home, Sublingual Ketamine Therapy Rapidly Improves Anxiety, Depressive Symptoms
08/02/2022
Sublingual, at-home ketamine-assisted therapy over 4 weeks was safe and effective for patients with moderate to severe anxiety and depression in what is thought to be the largest study to date of any type of ketamine treatment.
Sublingual, at-home ketamine-assisted therapy over 4 weeks was safe and effective for patients with moderate to severe anxiety and depression in what is thought to be the largest study to date of any type of ketamine treatment.
Sublingual, at-home...
08/02/2022
Psych Congress Network
News
Medication to Treat Alcohol Use Disorder Shows Promise in Phase 3 Trial
07/28/2022
Adial Pharmaceuticals announced that in its ONWARD Phase 3 clinical study, its AD04 medication achieved a statistically significant mean reduction in heavy drinking days among a prespecified group of “heavy drinkers” compared to a placebo.
Adial Pharmaceuticals announced that in its ONWARD Phase 3 clinical study, its AD04 medication achieved a statistically significant mean reduction in heavy drinking days among a prespecified group of “heavy drinkers” compared to a placebo.
Adial Pharmaceuticals announced...
07/28/2022
Psych Congress Network

Advertisement

News
Sleep Apnea Status Linked With White Matter Integrity, Cognition Over Time
07/26/2022
Obstructive sleep apnea (OSA) was associated with impaired cognitive performance and white matter integrity over 4 years of follow-up, according to study results published online in JAMA Network Open.
Obstructive sleep apnea (OSA) was associated with impaired cognitive performance and white matter integrity over 4 years of follow-up, according to study results published online in JAMA Network Open.
Obstructive sleep apnea (OSA)...
07/26/2022
Neurology
News
MDMA-Assisted Psychotherapy Phase II Trial Halted Amid Regulatory Concerns
07/26/2022
Citing patient safety concerns, Health Canada recently halted a Phase II clinical trial of MDMA-assisted psychotherapy being conducted in Toronto.
Citing patient safety concerns, Health Canada recently halted a Phase II clinical trial of MDMA-assisted psychotherapy being conducted in Toronto.
Citing patient safety concerns,...
07/26/2022
Psych Congress Network
News
Mindfulness Cognitive Group Therapy Decreases Anxiety, Avoidance in Treatment-Refractory Patients
07/25/2022
Mindfulness-based cognitive group therapy appears promising for the treatment of patients with anxiety disorder who have an insufficient response to first-line cognitive behavioral therapy.
Mindfulness-based cognitive group therapy appears promising for the treatment of patients with anxiety disorder who have an insufficient response to first-line cognitive behavioral therapy.
Mindfulness-based cognitive...
07/25/2022
Psych Congress Network

Advertisement

News
At-Home Ketamine Therapy Shows Promise in Treatment of Anxiety, Depression
07/25/2022
At-home, sublingual ketamine therapy was found to be a safe and effective treatment for anxiety and depression in a study co-authored by researchers from the Multidisciplinary Association for Psychedelic Studies (MAPS), the Cleveland Clinic,...
At-home, sublingual ketamine therapy was found to be a safe and effective treatment for anxiety and depression in a study co-authored by researchers from the Multidisciplinary Association for Psychedelic Studies (MAPS), the Cleveland Clinic,...
At-home, sublingual ketamine...
07/25/2022
Psych Congress Network
News
OCD More Than Triples Risk of Substance Misuse
07/22/2022
A diagnosis of obsessive-compulsive disorder (OCD) is associated with a 3.7-fold elevated risk of substance misuse, according to study results published online in JAMA Network Open.
A diagnosis of obsessive-compulsive disorder (OCD) is associated with a 3.7-fold elevated risk of substance misuse, according to study results published online in JAMA Network Open.
A diagnosis of...
07/22/2022
Psych Congress Network
News
Males Under 40 Face Highest Risk Related to Alcohol Consumption
07/20/2022
Individuals under the age of 40—particularly males—face higher risks from alcohol consumption than older adults and receive no health benefits from consuming alcohol, according to new research published this month in The Lancet.
Individuals under the age of 40—particularly males—face higher risks from alcohol consumption than older adults and receive no health benefits from consuming alcohol, according to new research published this month in The Lancet.
Individuals under the age of...
07/20/2022
Psych Congress Network

Advertisement

News
Balovaptan Fails to Improve Social Communication in Autism Spectrum Disorder
07/19/2022
Oral balovaptan did not demonstrate efficacy in improving socialization and communication in a randomized clinical trial of children and adolescents with autism spectrum disorder.
Oral balovaptan did not demonstrate efficacy in improving socialization and communication in a randomized clinical trial of children and adolescents with autism spectrum disorder.
Oral balovaptan did not...
07/19/2022
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use